Serum neuron specific enolase level as a prognostic factor in non-small cell lung cancer.
In 93 patients with inoperable non-small cell lung carcinoma who underwent chemotherapy including cisplatin, the prognostic value of 9 factors were determined using Cox's proportional hazard model. Univariate analysis revealed that patients with a performance status of grade 2 (p < 0.01) or 3 (p < 0.05), those with stage IV disease (p < 0.05), those with a serum neuron specific enolase (NSE) level > 7.0 ng/ml (p < 0.001), and those with a low serum albumin level (p < 0.05) had a significantly worse prognosis. Multivariate analysis showed that a performance status of 2 or 3 and a high NSE serum level were associated with a significantly worse prognosis. More attention should be paid to the serum NSE level in patients with non-small cell lung carcinoma, because it not only reflects the tumor volume, but is also a prognostic factor which is dependent on individual tumor characteristics.
Andoh
M
M
Fourth Department of Internal Medicine, Nippon Medical School, Tokyo.
Gemma
A
A
Takenaka
K
K
Hisakatsu
S
S
Yamada
K
K
Usuki
J
J
Hasegawa
K
K
Sakonji
M
M
Kudoh
S
S
Tsuboi
E
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010751:Phosphopyruvate Hydratase / Q000097:blood*; D011379:Prognosis
D010751:Phosphopyruvate Hydratase